|
| 37151021 | A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation. | J Oncol Pharm Pract | 2024 |
| 37953244 | Can we truly define 'Fitness' for CAR-T therapy in large B cell lymphoma patients? | Chin Clin Oncol | 2024 |
| 38055922 | Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective. | Blood Adv | 2024 |
| 36216657 | Serial Transthoracic Ultrasonography Studies in Hematopoietic Cell Transplant Patients: A Tool for Early Lung Pathology Detection. | Ultrasound Med Biol | 2023 |
| 37664800 | A new beginning: can omidubicel emerge as the next, viable alternative donor source? | Ther Adv Hematol | 2023 |
| 37522731 | Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. | Blood Adv | 2023 |
| 37749187 | Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002. | Bone Marrow Transplant | 2023 |
| 37703995 | Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial. | Transplant Cell Ther | 2023 |
| 37741763 | Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience. | Clin Lymphoma Myeloma Leuk | 2023 |
| 37120134 | Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. | Transplant Cell Ther | 2023 |
| 37287113 | A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma. | Leuk Lymphoma | 2023 |
| 37236188 | Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques. | Immunity | 2023 |
| 37364775 | Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient. | Transplant Cell Ther | 2023 |
| 37031746 | Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. | Transplant Cell Ther | 2023 |
| 36441905 | Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. | Blood Adv | 2023 |
| 36690537 | Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates. | Cytotherapy | 2023 |
| 36775201 | Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. | Transplant Cell Ther | 2023 |
| 36508286 | Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. | Blood Adv | 2023 |
| 36179986 | Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood. | Transplant Cell Ther | 2023 |
| 36355838 | Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. | Blood Adv | 2023 |
| 36380065 | Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL. | Nat Rev Clin Oncol | 2023 |
| 34686447 | Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma - The Oregon Health and Science University Experience. | Clin Lymphoma Myeloma Leuk | 2022 |
| 35439295 | Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. | Blood | 2022 |
| 35764288 | Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2022 |
| 35422192 | Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. | Leuk Lymphoma | 2022 |
| 35690221 | Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. | Ann Oncol | 2022 |
| 35687492 | Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. | Blood Adv | 2022 |
| 35850429 | Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. | Transplant Cell Ther | 2022 |
| 36594901 | Post-allogeneic stem cell transplant <i>FLT3</i>- targeted maintenance therapy: updates and considerations for clinical practice. | Arch Stem Cell Ther | 2022 |
| 35940526 | Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery. | Transplant Cell Ther | 2022 |
| 34978255 | Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. | Leuk Lymphoma | 2022 |
| 35030634 | Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. | Blood Adv | 2022 |
| 34904798 | Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. | N Engl J Med | 2022 |
| 34587551 | Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. | Transplant Cell Ther | 2022 |
| 34637965 | Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. | Transplant Cell Ther | 2022 |
| 32499241 | Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. | Haematologica | 2021 |
| 35590167 | The evolving need for patient reported outcome data in determining choice of immune therapy treatment. | Med | 2021 |
| 33901720 | Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or Relapse. | Transplant Cell Ther | 2021 |
| 33529419 | Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. | Am J Hematol | 2021 |
| 33775615 | Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. | Transplant Cell Ther | 2021 |
| 34496026 | Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. | Blood Adv | 2021 |
| 34461278 | Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. | Transplant Cell Ther | 2021 |
| 34516954 | Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. | Lancet Oncol | 2021 |
| 34106753 | Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. | J Clin Oncol | 2021 |
| 34273085 | Lifetime Costs for Treated Follicular Lymphoma Patients in the US. | Pharmacoeconomics | 2021 |
| 34157093 | Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. | Blood | 2021 |
| 34124796 | Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation. | Br J Haematol | 2021 |
| 33961341 | Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations. | Am J Transplant | 2021 |
| 34036237 | Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. | JCO Precis Oncol | 2021 |
| 33288862 | Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. | Bone Marrow Transplant | 2021 |